Active, Not Recruiting
An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia - CA209-7CK
Actualizada: 25 enero, 2022 | ClinicalTrials.gov
Imprimir Resumen
Detalles del estudio
Géneros
Rango de edad
Active, Not Recruiting
Opciones de tratamiento
Inclusion Criteria: - Adults with a primary diagnosis of melanoma with involvement of lymph nodes or metastatic disease who have undergone complete surgical removal and have no evidence of disease - Decision to treat with adjuvant nivolumab therapy has already been taken - Ability to provide written informed consent to participate in the study Exclusion Criteria: - Adults with a current diagnosis of persisting advanced melanoma - Adults currently enrolled in an interventional clinical trial for his/her melanoma treatment Other Inclusion/Exclusion criteria may apply.
Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica
